Fig. 2From: Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysisForest plot showing A empagliflozin users had significantly lower risk of death compared to dapagliflozin users among DM population B Sotagliflozin users had a lower risk of cardiovascular death and HHF in HF patients C Canagliflozin users had significantly lower risk of cardiovascular death and HHF in non-HF patients D Sotagliflozin users had a significant lower risk of MACE than placebo users, but other SGLT2 inhibitors didn’t for HF population E Less selective SGLT2 inhibitors(canagliflozin and sotagliflozin) users had significant lower risk of MACE compared with highly selective SGLT-2 inhibitors(dapagliflozin, empagliflozin, and ertugliflozin) users for HF patients. AKI acute kidney injury, DM Diabetes Mellitus, HF Heart failure, HHF hospitalization heart failure, MACE Major adverse cardiac events, SGLT2 Sodium–Glucose Cotransporter 2Back to article page